Invesco Nasdaq Biotechnology ETF

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

BCRX

QNRX

The Netherton syndrome market is projected to grow from 2026 to 2036, driven by new therapies like QRX003, BCX17725, and ATR-12. The U.S. is expected to lead in market size, with an increase in diagnosed cases due to better diagnostics. Current treatments are mainly symptomatic, highlighting the need for effective, targeted therapies. The development of these new drugs presents significant opportunities in addressing the unmet medical needs of Netherton syndrome patients.

prnewswire

BioCryst Pharma

Quoin Pharmaceuticals

Azitra

QUOIN PHARMACEUTICALS LTD SPON ADS EACH REP 1 ORD SHS

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

IMUX

BIIB

Immunic has appointed Michael W. Bonney as chair of the board, effective May 16, 2026, replacing interim chair Simona Skerjanec, who will remain a board member. Bonney has a strong background in the pharmaceutical industry, having previously held senior roles at Biogen and served as CEO of Cubist Pharmaceuticals, leading its sale to Merck for approximately USD 9.5 billion.

PUBT

Immunic

Merck

Biogen

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

BMRN

BioMarin Pharmaceutical (BMRN) has seen a decline in its stock price, down 4% in a day and 17% over three months, raising concerns about its valuation. Currently priced at $49.67, analysts estimate a fair value of $89.96, indicating potential undervaluation. However, there is significant disagreement among analysts regarding future earnings projections. The company's high P/E ratio of 35.7x compared to industry averages suggests valuation risks. Investors are advised to consider both opportunities and risks before making decisions.

Simplywall

BioMarin Pharma

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

WHO REPRESENTATIVE IN CONGO: MERCK & CO’S >< ERVEBO IS ONE OF THE POTENTIAL VACCINES THAT COULD PROVIDE PREVENTION AND PROTECTION AGAINST EBOLA

Unusual Whales

WHO REPRESENTATIVE IN CONGO: MERCK & CO’S >< ERVEBO IS ONE OF THE POTENTIAL VACCINES THAT COULD PROVIDE PREVENTION AND PROTECTION AGAINST EBOLA

ORKA

Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares at $59.07 each, totaling $607,830.30, representing a 38.55% decrease in his ownership. Post-sale, he holds 16,406 shares valued at $969,102.42. The transaction was made under a Rule 10b5-1 plan and disclosed to the SEC. The stock is currently trading down 5.8% at $58.34.

Oruka Therapeutics

Barclays

UBS Group AG

ROYAL BANK OF CANADA

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

BioMarin’s BMN 401 raised plasma PPi over 52 weeks in children but showed no meaningful rickets or growth improvement. Shares fell about 3% to ~$50.10 after the announcement.12HC Wainwright & Co. reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (BMRN) and lowered its price target for the stock from $55.00 to $50.00 per share.3

TradingView

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

ATYR

RBC Capital has maintained a Hold rating on aTyr Pharma (ATYR) with a price target of $1.00, while the shares closed at $0.50. Analyst Brian Abrahams has an average return of 10.7% and a 52.10% success rate. Wells Fargo also issued a Hold rating, while Piper Sandler maintained a Buy rating on May 12.

Tip Ranks

ATYR Pharma

Regeneron Pharma

Wells Fargo

Piper Sandler Cos

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

ATRA

Rosen Law Firm is reminding investors who purchased Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, of the May 22, 2026, lead plaintiff deadline for a securities fraud lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges that Atara made misleading statements regarding manufacturing issues and regulatory prospects, leading to investor damages when the truth emerged.

Atara Biotherap

21:12 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

LLYX

The company is riding an incredible tailwind.

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Eli Lilly stock: Next stop $2,000?

REGN

Levi & Korsinsky is investigating Regeneron Pharmaceuticals (REGN) following significant stock losses after the failure of its Phase 3 melanoma trial of fianlimab + Libtayo. The stock dropped over 10% after the trial did not meet its primary endpoint. Shareholders who suffered losses are encouraged to contact the firm for potential legal recourse.

Direxion S&P Biotech Bear 3X

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

Invesco Nasdaq Biotechnology ETF(IBBQ.US)

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

WHO REPRESENTATIVE IN CONGO: MERCK & CO’S >< ERVEBO IS ONE OF THE POTENTIAL VACCINES THAT COULD PROVIDE PREVENTION AND PROTECTION AGAINST EBOLA

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

21:12 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

Eli Lilly stock: Next stop $2,000?

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)